Home Drug IndexClinical Monograph

Ciprofloxacin Uses, Dosage, Side Effects & Warnings | DrugsAtlas

Authoritative Clinical Reference

Therapeutic Class

Antimicrobial

Subclass

Fluoroquinolone

Speciality

Infectious Disease

Schedule (India)

Schedule H

Routes

Oral, Intravenous, Ophthalmic, Otic

Formulations

Form	Strengths
Film-coated Tablets	250 mg; 500 mg; 750 mg
Extended-release Tablets	500 mg; 1000 mg
Oral Suspension	250 mg per 5 mL (limited availability)
IV Infusion	100 mg/50 mL; 200 mg/100 mL; 400 mg/200 mL
Eye Drops	0.3% w/v (5 mL, 10 mL)
Ear Drops	0.3% w/v (5 mL, 10 mL)
Eye Ointment	0.3% w/w

Form	Strengths
Film-coated Tablets	250 mg; 500 mg; 750 mg
Extended-release Tablets	500 mg; 1000 mg
Oral Suspension	250 mg per 5 mL (limited availability)
IV Infusion	100 mg/50 mL; 200 mg/100 mL; 400 mg/200 mL
Eye Drops	0.3% w/v (5 mL, 10 mL)
Ear Drops	0.3% w/v (5 mL, 10 mL)
Eye Ointment	0.3% w/w

Unidentified

Adult indications

INDICATIONS + DOSING — FOR CLINICIAN USE ONLY

Primary Indications (Approved / Standard in India)

1. Uncomplicated Urinary Tract Infection (Acute Cystitis)

Adults:

Parameter	Recommendation
Starting dose	250 mg orally every 12 hours
Titration	Not applicable
Usual maintenance dose	250–500 mg orally every 12 hours
Maximum dose	500 mg every 12 hours
Duration	3 days (women); 7 days (men)

Clinical Note: NOT first-line for uncomplicated UTI due to high resistance rates in India. Reserve for culture-confirmed susceptible organisms or when first-line agents (nitrofurantoin, fosfomycin) are contraindicated or have failed.

2. Complicated Urinary Tract Infection / Pyelonephritis

Adults — Oral:

Parameter	Recommendation
Starting dose	500 mg orally every 12 hours
Titration	Increase to 750 mg every 12 hours for severe infections
Usual maintenance dose	500–750 mg orally every 12 hours
Maximum dose	750 mg every 12 hours
Duration	7–14 days

Adults — Intravenous (Severe/Hospitalised):

Parameter	Recommendation
Starting dose	400 mg IV every 12 hours
Titration	May increase frequency to every 8 hours for severe infections
Usual maintenance dose	400 mg IV every 8–12 hours
Maximum dose	400 mg IV every 8 hours (1200 mg/day)
Duration	7–14 days; step-down to oral when clinically stable

3. Enteric Fever (Typhoid/Paratyphoid) — Only If Susceptible

Adults:

Parameter	Recommendation
Starting dose	500 mg orally every 12 hours
Titration	May increase to 750 mg every 12 hours for severe cases
Usual maintenance dose	500–750 mg orally every 12 hours
Maximum dose	750 mg every 12 hours
Duration	7–10 days (uncomplicated); 10–14 days (complicated)

Clinical Note: High fluoroquinolone resistance (>80% in many regions of India) limits empiric use. Use ONLY when culture and sensitivity confirms susceptibility. Azithromycin or ceftriaxone preferred for empiric therapy per ICMR guidelines.

4. Acute Bacterial Diarrhoea (Invasive — Shigella, Salmonella, Campylobacter)

Adults:

Parameter	Recommendation
Starting dose	500 mg orally every 12 hours
Titration	Not applicable
Usual maintenance dose	500 mg every 12 hours
Maximum dose	500 mg every 12 hours
Duration	3–5 days

Clinical Note: Reserve for moderate-severe invasive diarrhoea with systemic features. Azithromycin increasingly preferred due to quinolone resistance in enteric pathogens.

5. Skin and Soft Tissue Infections (Gram-Negative Susceptible Organisms)

Adults — Oral:

Parameter	Recommendation
Starting dose	500 mg orally every 12 hours
Titration	Increase to 750 mg every 12 hours for severe infections
Usual maintenance dose	500–750 mg orally every 12 hours
Maximum dose	750 mg every 12 hours
Duration	7–14 days

Adults — Intravenous:

Parameter	Recommendation
Starting dose	400 mg IV every 12 hours
Titration	Increase to every 8 hours for severe/complicated infections
Usual maintenance dose	400 mg IV every 8–12 hours
Maximum dose	400 mg IV every 8 hours
Duration	7–14 days

Clinical Note: Not effective against MRSA or streptococci. Use only when gram-negative susceptible organisms confirmed or strongly suspected (e.g., diabetic foot with Pseudomonas risk).

6. Hospital-Acquired Pneumonia / Ventilator-Associated Pneumonia (Including Pseudomonas Coverage)

Adults:

Parameter	Recommendation
Starting dose	400 mg IV every 8 hours
Titration	Not applicable
Usual maintenance dose	400 mg IV every 8 hours
Maximum dose	400 mg IV every 8 hours (1200 mg/day)
Duration	7–14 days based on clinical response

Clinical Note: Usually combined with anti-pseudomonal beta-lactam for HAP/VAP. Monotherapy not recommended for critically ill patients.

7. Intra-Abdominal Infections (In Combination with Metronidazole)

Adults:

Parameter	Recommendation
Starting dose	400 mg IV every 12 hours (with metronidazole)
Titration	May increase to every 8 hours for severe infections
Usual maintenance dose	400 mg IV every 8–12 hours
Maximum dose	400 mg IV every 8 hours
Duration	4–7 days with adequate source control

8. Bacterial Conjunctivitis (Ophthalmic)

Adults and Children:

Parameter	Recommendation
Starting dose	1–2 drops into affected eye(s) every 2 hours while awake
Titration	Reduce frequency as infection improves
Usual maintenance dose	1–2 drops every 4–6 hours
Maximum dose	2 drops every 2 hours (first 2 days)
Duration	7 days

9. Acute Otitis Externa / Chronic Suppurative Otitis Media (Otic)

Adults and Children:

Parameter	Recommendation
Starting dose	3–4 drops into affected ear(s) twice daily
Titration	Not applicable
Usual maintenance dose	3–4 drops twice daily
Maximum dose	4 drops three times daily
Duration	7–14 days

Secondary Indications — Adults (Off-label, if any)

Indication	Dose	Duration	Notes
Chronic Bacterial Prostatitis	500–750 mg orally every 12 hours	4–6 weeks	OFF-LABEL. Specialist only. One of few agents with good prostatic penetration. Culture-confirmed susceptibility required
Bone and Joint Infections (Osteomyelitis, Septic Arthritis)	750 mg orally every 12 hours OR 400 mg IV every 8–12 hours	6–12 weeks (osteomyelitis)	OFF-LABEL. Specialist only. Usually in combination with other agents (e.g., rifampicin for staphylococcal prosthetic joint infection). Based on orthopaedic infectious disease protocols
Post-Exposure Prophylaxis — Anthrax (Bioterrorism)	500 mg orally every 12 hours	60 days	OFF-LABEL. Public health emergency use. Per NCDC/ICMR guidelines
Neutropenic Fever (Low-Risk, Outpatient)	500–750 mg orally every 12 hours (with amoxicillin-clavulanate)	Until neutrophil recovery	OFF-LABEL. Specialist only. Based on oncology protocols for low-risk febrile neutropenia

Paediatric indications

PAEDIATRIC DOSING (Specialist Only)

Primary Indications (Approved / Standard in India)

General Principle: Ciprofloxacin is NOT routinely recommended in children <18 years due to risk of cartilage toxicity (arthropathy). Use ONLY when no suitable alternative exists and benefits outweigh risks. Requires specialist supervision.

1. Enteric Fever (MDR Typhoid) — Culture-Confirmed Susceptibility

Children ≥1 year:

Parameter	Recommendation
Starting dose	10–15 mg/kg orally every 12 hours
Titration	Not applicable
Usual maintenance dose	10–15 mg/kg every 12 hours
Maximum single dose	500 mg
Maximum daily dose	1000 mg
Duration	7–10 days

Clinical Note: Use only for culture-confirmed fluoroquinolone-susceptible strains when ceftriaxone/azithromycin not suitable.

2. Complicated Urinary Tract Infection / Pyelonephritis

Children ≥1 year:

Parameter	Recommendation
Starting dose	10 mg/kg orally/IV every 12 hours
Titration	Not applicable
Usual maintenance dose	10–15 mg/kg every 12 hours
Maximum single dose (Oral)	500 mg
Maximum single dose (IV)	400 mg
Duration	7–14 days

3. Pseudomonal Infections (Cystic Fibrosis, Immunocompromised)

Children ≥1 year:

Parameter	Recommendation
Starting dose	15 mg/kg orally/IV every 12 hours
Titration	May increase to 20 mg/kg every 12 hours for severe infections
Usual maintenance dose	15–20 mg/kg every 12 hours
Maximum single dose (Oral)	750 mg
Maximum single dose (IV)	400 mg
Duration	As per indication and specialist guidance

4. Ophthalmic Infections (Bacterial Conjunctivitis, Corneal Ulcer)

All ages (including neonates for topical use):

Parameter	Recommendation
Starting dose	1–2 drops every 2 hours while awake
Titration	Reduce frequency as infection improves
Usual maintenance dose	1–2 drops every 4–6 hours
Duration	7–14 days

5. Otitis Externa / Chronic Suppurative Otitis Media

Children ≥1 year:

Parameter	Recommendation
Starting dose	3 drops into affected ear twice daily
Usual maintenance dose	3 drops twice daily
Duration	7–14 days

Secondary Indications — Paediatrics (Off-label, if any)

Indication	Dose	Duration	Notes
Febrile Neutropenia (when IV not feasible)	10–15 mg/kg orally every 12 hours (max 500 mg/dose)	Until neutrophil recovery	OFF-LABEL. Specialist oncology supervision only. In combination with amoxicillin-clavulanate for outpatient low-risk neutropenia

Age Restrictions and Safety Monitoring

Age Group	Recommendation
<1 year	Avoid systemic use; topical ophthalmic/otic may be used with caution
1–18 years	Systemic use only when no alternative exists; specialist supervision mandatory
>18 years	Adult dosing applicable

Safety Monitoring in Paediatrics:

Monitor for musculoskeletal symptoms (joint pain, swelling, tendon pain) — discontinue if occurs
Baseline and periodic assessment of joints in prolonged therapy
LFTs if treatment >7 days
CNS symptoms (headache, confusion, seizures)

Renal Adjustments

Dose adjustment required based on creatinine clearance:

CrCl (mL/min)	Oral Dosing	IV Dosing
>50	No adjustment	No adjustment
30–50	250–500 mg every 12 hours	200–400 mg every 12 hours
10–29	250–500 mg every 18–24 hours	200–400 mg every 18–24 hours
<10	250–500 mg every 24 hours	200–400 mg every 24 hours
Haemodialysis	250–500 mg every 24 hours (dose after dialysis on dialysis days)	200–400 mg every 24 hours (dose after dialysis)
CAPD	250–500 mg every 24 hours	200–400 mg every 24 hours
CRRT	200–400 mg every 12 hours (adjust per effluent rate)	As per clinical response

Hepatic adjustment

Contraindications

Known hypersensitivity to ciprofloxacin or any fluoroquinolone antibiotic
Concurrent use with tizanidine — risk of severe hypotension and excessive sedation (pharmacokinetic interaction via CYP1A2 inhibition)
History of tendon disorder related to fluoroquinolone use (tendinitis, tendon rupture)
Myasthenia gravis — risk of severe exacerbation including respiratory failure

Cautions

History of epilepsy or conditions predisposing to seizures — lowers seizure threshold
Pre-existing QT prolongation or concurrent use of QT-prolonging drugs
Glucose-6-phosphate dehydrogenase (G6PD) deficiency — haemolytic reactions reported
Diabetes mellitus — risk of severe hypoglycaemia or hyperglycaemia
Elderly patients — increased risk of tendon rupture, QT prolongation, and CNS effects
Concurrent corticosteroid use — significantly increased tendon rupture risk
Renal impairment — requires dose adjustment
History of peripheral neuropathy
Aortic aneurysm or dissection risk factors — emerging data on association with aortic events

Pregnancy

Parameter	Recommendation
Overall safety	Generally AVOID; potential risk of fetal cartilage damage based on animal studies
Risk category	Category C (US legacy); Not recommended in pregnancy per Indian practice
Preferred alternatives	Cephalosporins (ceftriaxone, cefixime), nitrofurantoin (for UTI — avoid near term), azithromycin (for typhoid)
When it may be used	Only when no safer alternative available and maternal benefit clearly outweighs fetal risk; specialist decision
Monitoring	Fetal growth; maternal adverse reactions; avoid in first trimester if possible

Lactation

Parameter	Recommendation
Compatibility	Use with caution; excreted in breast milk
Drug levels in milk	Low to moderate; infant receives small amounts
Preferred alternatives	Amoxicillin, cephalosporins, azithromycin
Infant monitoring	Observe for diarrhoea, oral thrush, feeding difficulties; theoretical concern for cartilage effects (not proven in humans)

Note: If ciprofloxacin essential, consider temporary interruption of breastfeeding during treatment course.

Elderly

Parameter	Recommendation
Starting dose	Lower end of dosing range (250–500 mg orally or 200–400 mg IV every 12 hours)
Titration	Cautious; assess renal function before escalating
Renal consideration	Age-related decline in renal function common; calculate CrCl and adjust dose accordingly
Specific risks	Significantly increased risk of: Achilles tendon rupture (especially with concurrent steroids); QT prolongation and arrhythmias; CNS effects (confusion, hallucinations, delirium); hypoglycaemia (especially in diabetics on sulfonylureas/insulin)
Monitoring	ECG if cardiac risk factors; blood glucose in diabetics; tendon symptoms; mental status

Major drug interactions

Drug	Interaction	Recommendation
Tizanidine	CYP1A2 inhibition by ciprofloxacin causes 10-fold increase in tizanidine levels → severe hypotension, excessive sedation	CONTRAINDICATED — do not co-administer
Theophylline/Aminophylline	CYP1A2 inhibition → increased theophylline levels → toxicity (seizures, arrhythmias, nausea)	Reduce theophylline dose by 30–40%; monitor levels closely
QT-prolonging drugs (Amiodarone, Sotalol, Haloperidol, Ondansetron, Erythromycin)	Additive QT prolongation → risk of torsades de pointes	Avoid combination if possible; if essential, baseline and follow-up ECG; correct electrolytes
Warfarin/Acenocoumarol	Enhanced anticoagulant effect via CYP1A2 inhibition and gut flora alteration	Monitor INR closely (within 3–5 days of starting ciprofloxacin); adjust anticoagulant dose
Methotrexate	Reduced renal clearance of methotrexate → increased toxicity	Monitor for methotrexate toxicity; consider dose reduction or avoid combination
Duloxetine	CYP1A2 inhibition → increased duloxetine levels → serotonin syndrome risk	Avoid combination; if essential, use lowest duloxetine dose and monitor
Phenytoin	Altered phenytoin levels (increased or decreased)	Monitor phenytoin levels; adjust dose as needed

Moderate drug interactions

Drug	Interaction	Recommendation
Antacids (Aluminium/Magnesium hydroxide), Iron, Calcium, Zinc, Sucralfate	Form chelation complexes → significantly reduced ciprofloxacin absorption	Administer ciprofloxacin 2 hours before or 6 hours after these products
Dairy products / Calcium-fortified foods	Reduced absorption (less than antacids but still significant)	Avoid taking ciprofloxacin with dairy; may take with food otherwise
Sulfonylureas (Glibenclamide, Glimepiride) / Insulin	Risk of severe hypoglycaemia or hyperglycaemia	Monitor blood glucose closely; counsel patient about symptoms
Cyclosporine	Increased cyclosporine nephrotoxicity; ciprofloxacin levels may also increase	Monitor renal function and cyclosporine levels
NSAIDs	Potential increased risk of CNS stimulation and seizures	Use with caution, especially in patients with seizure history
Rifampicin	May reduce ciprofloxacin levels via enhanced metabolism	Monitor clinical efficacy; consider ciprofloxacin dose increase
Clozapine	CYP1A2 inhibition → increased clozapine levels → toxicity	Monitor clozapine levels and for adverse effects; dose reduction may be needed
Probenecid	Reduced renal clearance of ciprofloxacin → increased levels	Monitor for ciprofloxacin toxicity

Common Adverse effects'

Nausea and vomiting
Diarrhoea
Abdominal pain/discomfort
Headache
Dizziness
Rash and pruritus
Photosensitivity
Transient elevation of liver enzymes
Insomnia
Injection site reactions (IV use)

Serious Adverse effects

Adverse Effect	Clinical Notes
Tendinitis / Tendon rupture	Most commonly Achilles tendon; risk highest in elderly, those on corticosteroids, and renal transplant recipients. Discontinue immediately if tendon pain occurs; avoid exercise
QT prolongation / Torsades de pointes	Risk increased with electrolyte disturbances, concurrent QT-prolonging drugs, cardiac disease. ECG monitoring recommended in at-risk patients
Severe hypoglycaemia / Hyperglycaemia	Can be life-threatening; more common in diabetics on glucose-lowering therapy. Discontinue if severe dysglycaemia occurs
CNS toxicity (Seizures, Toxic psychosis, Hallucinations, Encephalopathy)	Risk increased in elderly, those with CNS disorders, renal impairment. Discontinue immediately
Peripheral neuropathy	May be irreversible; presents as pain, burning, tingling, numbness. Discontinue at first symptoms
Clostridioides difficile-associated diarrhoea (CDAD)	May occur during or after therapy. Discontinue and treat appropriately if confirmed
Anaphylaxis / Severe allergic reactions	Discontinue immediately; manage with adrenaline and supportive care
Stevens-Johnson Syndrome / Toxic Epidermal Necrolysis	Very rare; discontinue immediately; hospitalisation required
Hepatotoxicity (including fulminant hepatic failure)	Rare; discontinue if jaundice or significant LFT elevation
Aortic aneurysm / Dissection	Emerging association; use with caution in patients with risk factors (Marfan syndrome, elderly, hypertension)
Exacerbation of myasthenia gravis	May cause life-threatening respiratory failure

Monitoring requirements

Phase	Parameters
Baseline	Serum creatinine/eGFR, LFTs, blood glucose (diabetics), ECG (if cardiac risk factors or concurrent QT-prolonging drugs), allergy history
During treatment	Clinical response; tendon symptoms (pain, swelling — counsel patient to report); CNS symptoms; blood glucose in diabetics; signs of C. difficile infection
Prolonged therapy (>7–14 days)	LFTs weekly; renal function; CBC if indicated; reassess clinical need for continuation
High-risk patients	ECG monitoring for QT; enhanced glucose monitoring

Brands in India

Ciplox	Cipla	Tablets, IV, Eye/Ear drops
Cifran	Sun Pharma	Tablets, IV
Ciprobid	Zydus	Tablets
Quintor	Torrent	Tablets
Zoxan	FDC	Tablets
Alcipro	Alkem	Tablets, IV
Ciprofloxacin (Generic)	Multiple	All forms

Fixed-Dose Combinations (Note: Use rational combinations only):

Cifran-OZ, Ciplox-TZ (Ciprofloxacin + Tinidazole) — for mixed aerobic-anaerobic infections
Ciplox-D (Ciprofloxacin + Dexamethasone eye/ear drops) — for inflammatory infections

Price range (INR)

Formulation	Approximate Price
Tablet 250 mg (per tablet)	₹2–₹5
Tablet 500 mg (per tablet)	₹3–₹8
Tablet 750 mg (per tablet)	₹8–₹15
IV 200 mg/100 mL	₹25–₹60
IV 400 mg/200 mL	₹40–₹90
Eye drops 0.3% (5 mL)	₹15–₹40
Ear drops 0.3% (5 mL)	₹15–₹40

Regulatory Note: Listed under NLEM 2022 (select formulations). NPPA price-controlled. Available through government supply at lower rates.

Clinical pearls'

Resistance is the major issue: Fluoroquinolone resistance in enteric pathogens exceeds 80% in many parts of India. NEVER use empirically for typhoid — always obtain culture/sensitivity. Azithromycin or ceftriaxone preferred for empiric enteric fever treatment.
Dairy and antacid timing: Ciprofloxacin absorption significantly reduced by dairy, antacids, iron, and calcium supplements. Administer 2 hours before or 6 hours after these products to ensure therapeutic levels.
Tendon rupture warning: Educate all patients, especially elderly and those on corticosteroids, to immediately stop ciprofloxacin and rest the affected limb if tendon pain occurs. Risk persists for months after stopping the drug.
QT risk assessment: Before prescribing, check for concurrent QT-prolonging medications (common in India: azithromycin, ondansetron, antipsychotics). Consider baseline ECG in elderly or those with cardiac history.
Diabetic caution: Both severe hypoglycaemia and hyperglycaemia reported. Counsel diabetic patients on sulfonylureas or insulin to monitor glucose closely and recognise warning symptoms.
Not for routine use in children: Systemic ciprofloxacin in children should be an exception, not routine. Document indication and lack of alternatives. Topical ophthalmic/otic use is generally safe.

Version

RxIndia v1.0 — 03 May 2025

Reference

- CDSCO Drug Database and Product Inserts
- Indian Pharmacopoeia 2022
- National List of Essential Medicines (NLEM) 2022
- API Textbook of Medicine (11th Edition)
- ICMR Antimicrobial Resistance Surveillance Network Reports
- ICMR Treatment Guidelines for Antimicrobial Use in Common Syndromes
- AIIMS Antimicrobial Policy and Treatment Guidelines
- NCDC Typhoid and Enteric Fever Treatment Modules
- IAP Textbook of Paediatric Infectious Diseases
- Goodman & Gilman's The Pharmacological Basis of Therapeutics
- Harrison's Principles of Internal Medicine (21st Edition)

⚖️

Clinical Responsibility

This platform is designed strictly for healthcare professionals. Data provided is synthesized from authoritative pharmacological sources and clinical registries. Do not use for consumer medical decisions. Always verify critical dosing and contraindications with official institutional protocols and peer-reviewed journals.

Content Feedback

Is this information helpful?

Help us improve our clinical database for the medical community.

RxIndia

Loading clinical data...